biogen
idec completes a merger with biogen, inc. , creating biogen idec inc .
principal subsidiaries: biogen idec ma inc. ; biogen idec u. s. corporation; biogen idec u. s. limited partnership; biogen idec holding i inc. ; biogen holding ii inc. ; the biogen idec foundation inc. ; biogen idec (rtp) realty l. l. c. ; biogen idec realty corporation; biogen idec realty limited partnership; biogen idec u. s. west corporation; biogen idec u. s. pacific corporation; biogen idec nobel research center, l. l. c. ; biogen idec trade services building, l. l. c. ; biogen idec manufacturing operations, l. l. c. ; biogen idec canada inc. ; biogen idec austria gmbh; biogen idec belgium s. a. / n. v. ; biogen idec b. v. (netherlands); biogen idec international b. v. (netherlands); biogen idec (denmark) a / s; biogen idec (denmark) manufacturing aps; biogen idec finland oy; biogen idec (france); biogen idec gmbh (germany); biogen iberia sl (spain); biogen idec limited (u. k .); biogen idec norway as; biogen idec portugal; biogen idec sweden ab; biogen idec (switzerland) gmbh; biogen dompe s. r. l. (italy); biogen dompe ag (switzerland); biogen idec australia pty. ltd. ; biogen idec japan ltd. ; idec seiyaku (japan); biogen idec (bermuda) investments limited; biogen idec (bermuda) investments ii limited; biotech manufacturing c. v. (netherlands) .
you are now leaving biogen australia’s corporate website to a third party site that manages links to product information and consumer medicine information, on biogen’s behalf .
the acquisition supports biogen' s goal to develop multiple sclerosis products, biogen said, news sources report. financial terms of the agreement were not disclosed .
these terms and conditions of use describe the terms and conditions applicable to your use of biogen inc. ’s (“biogen”) website. find out more .
have similar therapies in development that could eat into biogen' s market share. will biogen sew up the hemophilia b market only to watch it quickly unravel ?
learn how biogen, sobi and the wfh are impacting hemophilia around the globe .
these terms and conditions of use describe the terms and conditions applicable to your use of biogen idec ltd. ’s (“biogen”) website. find out more .
biogen will spin off its hemophilia drug business as a separate company early next year .
the study is funded by biogen. dr sandrock is an employee of biogen. disclosures for the coauthors are in the paper. dr hendrix has disclosed no relevant financial relationships .
as a wellness company deeply committed to helping south africans become more active and healthy, biogen have forged a partnership with avianto trails to form the biogen sports park @ avianto .
idec to merge with biogen in $ 6. 8 billion deal - the new york times
at biogen, our mission is clear: we are pioneers in neuroscience. biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases .
skyland analytics appoints james c. mullen, former biogen and patheon ceo, to advisory board
our target price for biogen (consolidated) is $ 338. 50 per share. this reflects biogen’s robust ms drug portfolio, impending spin - off and initiatives to diversify into new disease areas. this suggests about 20% upside from biogen’s current stock price of $ 283. our fair value for bioverativ is $ 6. 1 billion (or $ 27. 75 per biogen share). our valuation for core biogen (biogen without bioverativ) is $ 61 billion (or $ 278. 25 per biogen share). the record date for the spin - off is january 17 th. the spin ratio if 1: 2, implying each biogen shareholder will receive 1 share of bioverativ shares for every 2 shares of biib .
tennille discusses her role in supporting patients living with devastating neurological diseases who are taking biogen medicines .
biogen is committed to working with advocacy and patient organizations as they serve the communities they represent .
official twitter channel for biogen. focused on cutting - edge science and medicine. community guidelines :
karol discusses how biogen is using human genetics to identify targets for new drugs. karol’s work in alzheimer’s disease is an example of how biogen is working to develop therapies that could address unmet need .
in all, the restructuring process will cost biogen up to $ 95 million in the fourth quarter .
you are now leaving biogen’s corporate website. we encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from biogen’s standards .
biogen and eisai announced positive topline results from their phase ii clinical trial of ban2401 in alzheimer’s disease .
biogen signed an exclusive option deal with tokyo - based tms for tms - 007 and backup compounds .
you are now leaving biogen canada’s website. we encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from biogen’s standards .
adam feneley, managing director, biogen, commented: “­the acquisition is another exciting milestone in biogen’s history which further enhances the company’s reputation as the number one food waste to renewable energy company in the uk. the investment is excellent news for biogen and marks the next stage of growth for the business. ”
under the terms of the deal, each biogen share will be exchanged for 1. 15 shares of idec. based on friday' s closing prices, there was no premium being paid to biogen shareholders .
swedish partners just how much biogen idec stands to keep from alprolix sales is still an unknown. when biogen acquired the therapy, it also inherited a complicated collaboration agreement with swedish orphan biovitrum, or sobi .
you are now leaving biogen australia’s corporate website. we encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from biogen’s standards .
but with all of this good news, biogen stock is trading at nearly the same level as it did at the beginning of 2017. do biogen shareholders have something to worry about? i think so .
'' where we were going with biogen was to build things that idec already had and where idec was going was to build things that biogen already had,'' mr. mullen said in an interview .
nonetheless, biogen investors in particular will want to keep a close eye on this market and its potential .
biogen develops, manufactures and markets innovative therapies for patients living with serious neurological, autoimmune and hematologic disorders .
at biogen, we are dedicated to making an impact on local communities, scientific education and the environment .
biogen develops, manufactures and markets innovative therapies for patients living with serious neurological, autoimmune and rare diseases .
you are now leaving biogen international' s website. we encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from biogen’s standards .
biogen shares rose $ 24. 31, or 9. 4 percent, to $ 284. 18 .
you are now leaving biogen idec ltd' s website. we encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from biogen’s standards .
biogen also discontinued a number of programs, including the phase 3 program for tecfidera, a multiple sclerosis drug .
biogen' s alprolix is now the most convenient hemophilia b treatment available, but competition is on the way .
at biogen, we are committed to improving the lives of patients living with serious illnesses and pursuing new treatments .
biogen idec has moved to beef up its pipeline by acquiring syntonix pharmaceuticals for $ 40 million down and up to $ 80 million in milestone payments. biogen idec says it will maintain syntonix' s 25, 000 - square - foot facility in waltham, ma. biogen gains a lead product for hemophilia b and technology for developing inhalable treatments .
) - - may 31, 2006 - - biogen idec (nasdaq: biib) and fumapharm ag, a privately held pharmaceutical company, today announced that they have signed a definitive agreement for the acquisition of fumapharm by biogen idec .
at biogen, we develop, market and manufacture therapies for people living with serious neurological, autoimmune and rare diseases .
find biogen’s current and historical stock information. view our upcoming events and latest webcasts. find financial statements and reports .
idec shareholders will own 50. 5 percent of the combined company, which will be based in biogen' s hometown, cambridge. james c. mullen, chairman and chief executive of biogen, will be chief executive of biogen idec, while dr. rastetter of idec will be executive chairman. the board will be split evenly between the two companies .
sobi has the option to pay for final development and commercialization activities in europe and nearby regions, then pay a double - digit royalty to biogen on those sales. sobi would also pay biogen for a share of past development costs in the region. in return, sobi would receive double - digit royalties from biogen on sales outside of sobi' s territory .
on biogen' s annual day of service, our employees give back to the communities in which we live and work .
scientific discovery is our core. at biogen, we relentlessly pursue new therapies for diseases with few or no treatment options .
stocks to watch: boeing, apple, u. s. steel, mcdonald’s, microsemi, nordstrom, gap, biogen
anaerobic digestion company, biogen, has been purchased for an undisclosed sum from joint venture shareholders bedfordia group and kier group .
biogen has a great thing going with spinraza, but there are big questions for its multiple sclerosis franchise and pipeline prospects .
at biogen, our mission is clear: we are pioneers in neuroscience. since our founding in 1978 as one of the world’s first global biotechnology companies, biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases .
biogen contributes to the communities where we live. we are committed to our employees, diversity and inclusion, and environmental sustainability .
krasner, jeffrey ,
biogen, idec complete merger ,
boston globe, november 13, 2003, p. b3 .
third party sites biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites with the exception that the third party site posts copies of the approved product information and consumer medicine information for biogen products .
at biogen, we work with healthcare professionals to ensure the therapies we create can reach those that need them. read more .
to learn more about biogen' s executive leadership based in cambridge, ma, usa, click here for our corporate website .
one factor that could change biogen' s valuation are the results, expected this summer, of a late - stage clinical trial for its experimental drug antegren, for crohn' s disease, a bowel inflammation. antegren could be biogen' s next product .
third party sites biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. additionally, the presence of this link does not imply the third party site' s endorsement of biogen or this website .
biogen is expecting data this year on a closely watched medicine known as anti - lingo that could become the first to restore nerve damage caused by multiple sclerosis. based on the phase ii data, biogen will decide whether to proceed to a pivotal registration trial .
explore the latest biogen news and information including all current and archived press releases. you can also sign up to receive email alerts .
at biogen, we discover, develop, manufacture and commercialize innovative therapies for people living with serious neurological, autoimmune and rare diseases .
biogen is one of the world’s leading biotechnology companies, with a focus on developing therapies for serious neurological, autoimmune and rare diseases .
turnaround trio: marketing boss tony kingsley, research chief doug williams, and ceo george scangos have made biogen idec a favorite of investors .
the biotech sector has been slammed this year on concerns about price gouging. biogen shares are down 21% year - to - date .
biogen announced it will host a live webcast providing an overview of its efforts targeting acute ischemic stroke on thursday, june 28, 2018 .
gilmore o’neill, formerly biogen’s senior vice president, late - stage clinical development, jumped ship and will be sarepta therapeutics’ chief medical officer .
biogen was established in 2005 by bedfordia chairman, john ibbett. ancala bioenergy ltd is an infrastructure investment vehicle managed by ancala partners llp .
biogen respects your skills and appreciates your contributions. work environment and technical tools available are excellent. it department is responsive to all requests .
the companies do have somewhat complementary products. idec has specialized in cancer and was moving into autoimmune diseases. biogen started with drugs for autoimmune diseases and was moving into cancer. indeed, merger talks began earlier this year after biogen licensed some of its cancer drug candidates to idec .
biogen’s introducing investors to its hemophilia spinoff - - and the company may be hoping it’ll take some attention away from recent buyout buzz, too .
according to a press release, biogen expects to complete the majority of the layoffs by the end of 2015, and is notifying affected employees .
the hemophilia drug franchise that biogen inc. plans to spin off as a separate company early next year has been given a name: bioverativ .
please be advised that all legitimate correspondence from a biogen employee will come from
@ urltoken
or “ @ brassring. com” email accounts .
“being at biogen has changed me as a scientist and the way i think about asking questions that could potentially make a difference for patients. ”
much like the periodic table of elements documents the building blocks of the universe around us, the biogen elements give shape to our company’s culture .
in 2016, biogen spent $ 106 million on advertising, versus $ 108. 6 million in 2015 and $ 92. 9 million in 2014 .
even so, scangos said last february, they “still have no strategic alignment with the rest of what we’re doing. ” bioverativ’s cox, a longtime biogen manufacturing executive, says that biogen had to make some decisions about how to allocate its capital. some $ 1 billion or more could be needed for aducanumab’s phase 3 trials alone. though the hemophilia products are profitable, they were a small part of biogen and didn’t really “move the needle, ” he says. despite rumors biogen was shopping the business, no deal ever materialized, and the bioverativ spin - out was formally announced last may .
biogen reported encouraging results from an early - stage study of aducanumab in the fourth quarter of 2016. it' s possible that the experimental drug could prove successful where others haven' t. however, there is certainly a high level of risk associated with biogen' s alzheimer' s disease efforts .
biogen idec creates new standards of care in oncology, neurology and immunology. as a global leader in the development, manufacturing, and commercialization of novel therapies, biogen idec transforms scientific discoveries into advances in human healthcare. for product labeling, press releases and additional information about the company, please visit urltoken .
the pharmaceutical company merger spree has produced corporate names like glaxosmithkline and astrazeneca. now the biotechnology industry is getting its own combination nameplate - - biogen idec .
cambridge, massachusetts - based biogen exercised its option to acquire additional shares of samsung bioepis, a joint venture with samsung biologics that was founded in 2012 .
global haemoglobinopathies market to reach $ 8. 99 billion by 2022 – leading players are gamida cell, alnylam pharmaceuticals, biogen idec, genetix pharmaceuticals and more
excluding special items, such as restructuring costs, biogen earned $ 4. 50 per share, handily beating wall street expectations of $ 4. 08 .
bioverativ will market biogen’s two hemophilia drugs, eloctate and alprolix, both approved by the food and drug administration in 2014, and work to develop other treatments for blood disorders. it will be led by chief executive john g. cox, who has been the biogen executive vice president for pharmaceuticals operation and technology .
“to me, it’s a rational split, ” says jonathan gertler, ceo of biotech consulting firm back bay life science advisors. biogen removed the “distraction” of a hemophilia business that the company couldn’t spend the time or resources trying to defend or bolster. “that’s not something that’s core to biogen, ” he says .
biogen acquired eloctate, which treats hemophilia a, and alprolix, which treats hemophilia b, through its $ 120 million buyout of syntonix pharmaceuticals inc. of waltham in 2007. the two drugs had combined sales of $ 554 million last year, about 5 percent of biogen’s overall revenue of $ 10. 8 billion .
as a leading company in the fight against multiple sclerosis, biogen is applying its expertise to help address some of most challenging and complex diseases of the brain .
we encourage you to read and evaluate terms of use, privacy, security and other similar policies of the destination site as they may differ from biogen’s standards .
john cox has served in his current position since june 2010. he joined biogen in 2003 and has held several senior executive positions with us, including senior vice president of technical operations, senior vice president of global manufacturing, and vice president of manufacturing and general manager of biogen’s operations in research triangle park, north carolina .
biogen idec has agreed to pay convergence shareholders $ 200 million upfront. the shareholders are also eligible to receive up to $ 475 million in payments tied to milestones .
as a global leader in biomanufacturing and serving niche markets, biogen idec is well - poised to deliver on the promise of hemophilia therapies that require less frequent dosing .
scangos viewed biogen’s hemophilia business—acquired through a $ 120 million buyout of syntonix pharmaceuticals in 2007—as an outlier. at a conference last february, he said he toyed with the idea of divesting the assets when he joined biogen in 2010. but he ultimately kept them, and the deal turned out very well for biogen: syntonix yielded two fda approved drugs known as eloctate and alprolix—regular infusions of which help hemophilia a and b patients avoid dangerous bleeds. the two drugs generated about $ 560 million in 2015 .
leadership development program associate salaries at biogen can range from $ 68, 814 - $ 75, 102. this estimate is based upon 1 biogen leadership development program associate salary report (s) provided by employees or estimated based upon statistical methods. see all leadership development program associate salaries to learn how this stacks up in the market .
biogen idec has said it will acquire privately - held swiss drugmaker fumapharm, adding a marketed drug for psoriasis to its portfolio and boosting its pipeline of multiple sclerosis treatments .
founded in 1978, biogen is the world’s oldest independent biotechnology company. patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $ 5 billion in annual revenues. biogen has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (als) and hemophilia by 2015 .
how does a fledgling company become an industry powerhouse? by managing itself professionally and betting on the right products. the case of biogen shows how it can be done .
won u. s. approval for ocrevus in march. although biogen originally developed the drug, roche licensed it and will keep the lion' s share of profits .
biogen' s hopes are pinned largely on spinraza for now. there' s no doubt that the drug will be a big success. analysts think spinraza could reach peak annual sales of around $ 2. 5 billion. biogen will have to pay royalties to ionis, but it will reap most of the rewards from the sma drug .
biogen forecast 2016 adjusted earnings of $ 18. 30 to $ 18. 60 per share and revenue of $ 11. 1 billion to $ 11. 3 billion .
at the time, almost nobody outside biogen and its academic collaborators believed this. the prevailing thought was that the two forms of beta interferon were essentially similar and at best biogen might get f. d. a. approval only to fight a bruising marketing war with berlex for half of a relatively small market .
wall street doubted avonex ,
said jeffrey casdin, an investment banker with hambrecht & quist, who has followed biogen closely .
i don' t think anyone counted on its working .
for help in planning a competitive strategy, biogen turned to joseph nemec jr. , a senior vice president in booz - allen & hamilton' s new york office, who had been a consultant to the company since 1985, when he was brought in to conduct a complete strategic review for james l. vincent, biogen' s chairman .
biogen, one of the largest biotechnology companies in the world, was at a crossroads in 2016. an experimental drug for the memory - robbing scourge, alzheimer’s disease, had shown signs of promise. that meant long, expensive, and risky phase 3 trials lay ahead for biogen to see if the early signals were more than a mirage .
'' biogen idec really becomes an incredible powerhouse,'' william h. rastetter, the chairman and chief executive of idec, said in a conference call with analysts .
“this acquisition supports our goal of developing innovative therapeutic options for people living with ms ,
said james mullen, biogen' s president and chief executive, in a statement .
) - - biogen idec (nasdaq: biib) and syntonix pharmaceuticals today announced that the companies have signed a definitive agreement for the acquisition of syntonix by biogen idec. syntonix, a privately held biopharmaceutical company focused on discovering and developing long - acting therapeutic products to improve treatment regimens for chronic diseases, has multiple pre - clinical programs in hemophilia .
from additional data or analysis, that regulatory authorities may require additional information, further studies, or may fail to approve the drug, or that the company may encounter other unexpected hurdles. for more detailed information on the risks and uncertainties associated with biogen idec' s drug development and other activities, see the periodic reports of biogen idec inc. filed with the securities and exchange commission. biogen idec assumes no obligation to update any forward - looking statements, whether as a result of new information, future events or otherwise .
the us is biogen' s largest market, bringing in more than 60% of total revenues. europe follows, with germany alone representing more than 5% of revenues .
the successful completion of the sale will mean further growth opportunities for biogen and provide an established platform for ancala’s expansion in the waste - to - energy sector, it says .
biogen achieved its success through the years on the strength of its multiple sclerosis (ms) drugs. however, the company' s ms franchise appears to be losing steam .
another similarity to big pharmaceutical companies is that the big biotechnology companies themselves are looking to license products from smaller biotechnology companies to spur their growth. biogen and idec executives said they expected half the products in biogen idec' s pipeline in 2010 would be licensed from others, and a reason for the merger was to be able to better compete for such deals .
the companies are currently evaluating experimental drug bg - 12 in a range of diseases, including multiple sclerosis and psoriasis. biogen licensed the worldwide rights to bg - 12 from the swiss company in 2003. additionally, fumapharm sells psoriasis drug fumaderm in germany and biogen said it plans to take over the drug' s manufacturing and marketing once the acquisition is final .
neuropathic pain is also the indication of a phase ii biogen idec compound, neublastin. as of november 20, 2014, biogen idec was recruiting participants for a phase ii study designed to assess the efficacy of intravenous neublastin in improving pain in painful lumbar radiculopathy participants when administered three times per week for one week, according to a posting on clinicaltrials. gov .
avonex is marketed through biogen' s direct sales force to specialist physicians and hospitals in north america, europe, and select other countries around the globe. the company also handles global marketing efforts for tysabri. genentech handles sales and marketing duties for rituxan, while marketing duties for fampyra are split with acorda (biogen sells the drug in europe and canada) .
biogen’s quarterly results should help put a difficult 2015 in the rear view mirror and allow for a renewed focus on potentially important drugs the u. s. biotech company is developing .
the sweeping cuts follow months of scrutiny tied to biogen' s ms franchise, perceived by analysts to be underperforming. the company is facing more and more competition in its home territory as new oral and injectable therapies hit the market, and a handful of r & d setbacks over the last year has intensified questions about biogen' s strategy for future growth .
howell, donna ,
idec pharmaceuticals scoops up biogen in the largest biotech merger since' 01 ,
investor' s business daily, june 24, 2003, p. a1 .
bioverativ was spun - off by biogen inc. (nasdaq: biib) in early 2017 so it could separate its global hemophilia business into an independent, publicly traded global biotechnology company .
biogen should be able to still grow earnings, albeit slowly, with the current ms franchise and good progress for spinraza. and if the company' s alzheimer' s disease program is successful, that would be a game changer. biogen investors probably should be at least somewhat worried about the challenges facing the biotech. however, there' s no need for panic .
biogen idec is perfectly positioned to continue the development of bg - 12 because of its global commercial and regulatory experience and unsurpassed expertise in ms. we are proud of the work that fumapharm has accomplished in the last 20 years and are confident that biogen idec will continue our legacy of helping patients ,
said dr. hans peter strebel, chairman and ceo of fumapharm .
small companies with large competitors must ever seek leverage. as biogen approached the introduction of its first drug, the company found some areas of expertise were too costly or time - consuming to build internally. biogen turned to outside consultants for matters as diverse as strategic planning and systems implementation. and for one critical process, the company even tapped the expertise of large pharmaceutical companies .
biogen idec and fumapharm have been collaborating on a drug for multiple sclerosis and psoriasis, bg - 12, since october 2003. this agent has already cleared one phase iii study in psoriasis – a sector which biogen idec recently exited by selling off rights to its amevive (alefacept) treatment to japanese drugmaker astellas - with positive phase ii data in multiple sclerosis reported earlier this week .
biogen has expanded its operations through purchases of drug development firms, as well as by purchasing commercialized and development - stage drugs. in 2015 the company acquired uk - based convergence pharmaceuticals, a clinical - stage biopharmaceutical, for $ 200. 1 million. the deal added convergence' s cnv1014802 candidate (for the treatment of trigeminal neuralgia and sciatica) to biogen' s pipeline .
on wednesday, biogen said u. s. tecfidera demand had stabilized, while sales were growing in europe, allowing for a renewed focus on the company’s promising stable of drugs in development .
so biogen had to raise money, cut expenses and build a senior management team. wall street had written off biogen, but mr. vincent' s track record in his previous jobs gave the company a chance to have its proposals heard, said frederick frank, an investment banker with lehman brothers, who represented the company. mr. vincent' s credibility, coupled with an innovative convertible preferred offering that allowed investors to receive a dividend that was sheltered from taxes by biogen' s losses, allowed the company to raise $ 65 million in the tough market of 1986 .
still, dr. rastetter said combining product portfolios with biogen would allow idec to'' avoid the growing pains and fits and starts of organic growth, which is an arduous process.''
biogen is more focused than ever on the areas where we can have the greatest impact. we built our business by putting science and patients at the center of every decision and investment we make .
for any business, in any competitive industry, the transition from research organization to operating company is critical. james l. vincent, biogen' s chairman, calls it
transforming knowledge into product .
like adolescence, this corporate coming of age is rarely painless or predictable; at biogen, the challenge was heightened by a cash crisis brought on by the profligacy of its early management .
products in biogen' s pipeline include the anti - lingo program for ms, ban2401 (in collaboration with eisai) for alzheimer' s disease, and stx - 100 for idiopathic pulmonary fibrosis .
keith speights has no position in any stocks mentioned. the motley fool owns shares of and recommends biogen and ionis pharmaceuticals. the motley fool recommends bioverativ. the motley fool has a disclosure policy .
biogen idec is dedicated to pursuing the creativity of science. the company' s products and development programs address a variety of key medical needs in the areas of oncology, neurology, dermatology and rheumatology .
with the filing of its application, which occupied 32 feet of shelf space, biogen entered a period of frenzied activity. complicating matters, the german partner that had supplied beta interferon for the clinical trials declared bankruptcy, forcing biogen to jump - start production in a pilot plant in cambridge, at a cost of $ 10 million, and requiring another level of f. d. a. approval .
given that the hemophilia products offered some financial stability and growth for biogen, there was some apprehension from analysts when biogen decided to toss them aside. at the time of the spin - out, for instance, leerink partners biotech analyst geoffrey porges called it a “somewhat surprising move, ” noting the hemophilia products were fast - growing drugs “buffering…the negative headwinds” facing the rest of biogen’s business and the company would “more or less tread water” until the aducanumab data in 2019. rbc capital markets’ micahel yee predicted “some head - scratching amongst investors” who “want more growth and diversification, not less. ” others disagree .
biogen is enrolling patients in two late stage trials of aducanumab, the alzheimer’s disease drug that generated excitement last year with early data that demonstrated reduction in amyloid plaque in the brain and some cognitive improvement .
but while going outside for help with the heavy lifting, biogen' s management also looked inside during this pivotal period. at many larger drug companies, the leading scientists have little to do with a molecule once it passes from discovery to the trial process and ultimately to market, as it ceases to be a matter of science and becomes an engineering problem and a marketing issue. not so at biogen .
another drug, ms treatment fampyra (also known as ampyra), is sold in partnership with acorda therapeutics. biogen is also co - marketing zinbryta, another ms treatment, in the us with abbvie .
to be sure, there were twists and turns in biogen' s road to commercialization that could occur only in a company balanced on the leading edge of science. but the company' s successful navigation of that journey reflects many more pragmatic disciplines: the timely addition of senior management, the willingness to make tough decisions without flinching, the balancing of internal capabilities and outsourcing and an early devotion to customer service. within seven months of its introduction, biogen' s first drug had captured more than a 50 percent share of its target market, and biogen is now the second largest independent biotech company, behind amgen inc .
during this same period, biogen' s scientists zeroed in on two drug candidates. one, which was ultimately named hirulog, was an anticoagulant, meant to be given to heart patients to prevent blood clotting. the drug was meant to replace heparin, an older drug that is inexpensive and effective but has problematic side effects, including bleeding. biogen' s scientists believed hirulog would be both safer and more effective .
limited resources meant biogen chose whenever possible to use off - the - shelf software, primarily from the oracle corporation, rather than build custom applications. one exception was
integrated customer,'' a custom database combining commercial third - party data with biogen' s own sales figures .
that was very important for them, to get a picture of how the market was responding ,
mr. kenneally said .
by design, biogen under scangos amassed a risky, neuroscience - focused pipeline including a group of experimental alzheimer’s drugs in mid - and - late stage testing. under his watch, biogen has restructured and cut a number of jobs to support its risk - heavy investments, halting preclinical work in a variety of other areas. in the meantime, its share price has been on a rollercoaster—from less than $ 50 when scangos joined to highs of over $ 475 in march 2015 to the roughly $ 275 it trades at today—as wall street grew frustrated at biogen’s hesitance to pull the trigger on a transformative acquisition that can offset its risk .
each company has a billion - dollar drug - - idec' s rituxan for non - hodgkin' s lymphoma and biogen' s avonex for multiple sclerosis. each also has a second drug on the market. but those products - - idec' s zevalin, also for lymphoma, and biogen' s amevive, for psoriasis - - are off to somewhat slow starts and some analysts doubt they will become big sellers .
biogen idec signed a definitive agreement to acquire privately - held fumapharm, the companies announced wednesday. the transaction, which was approved by both companies' boards, is expected to close within the next two months .
biogen has offices in the us, australia, canada, japan, the us, and several european countries. it has direct sales operations in about 30 countries and operates through distribution partners in another 60 countries .
biogen media contact: jason glashow, + 1 781 - 464 - 3260 public. affairs @ urltoken or investor contact: carlo tanzi, ph. d. , + 1 781 - 464 - 2442 ir @ urltoken
the war games persuaded biogen to price avonex the same as betaseron. a higher price might have created roadblocks for patients trying to get reimbursement from medicare and insurers unless avonex' s superiority could be proved, which would be a scientifically onerous task. and a lower price was unlikely to generate enough additional volume to offset the lower profit margins. biogen executives say the war game proved a fairly accurate predictor of how berlex would compete .
biogen’s seven anaerobic digestion plants recycle a quarter of a million tonnes of food waste annually from supermarkets, food manufacturers, the hospitality industry and local authorities to produce 13mw of renewable energy and a nutrient - rich biofertiliser .
on the pipeline side, biogen is walking away from its plans to develop the oral multiple sclerosis drug tecfidera for the secondary - progressive form of the disease, cutting a phase ii lupus program targeting the tweak immune cell, and discontinuing some preclinical projects in immunology and fibrosis research, the company said. biogen is also abandoning its ambitions of getting the injectable drug tysabri approved for secondary - progressive ms after reporting negative phase iii results wednesday .
australia' s csl limited also has a next - generation factor 9 replacement therapy in late - stage development. csl954 demonstrated a 92 hour half - life, putting it about halfway between biogen and novo' s offerings .
our employees are vitally important to the success of our work in supporting patients. we empower our employees to build rewarding careers at biogen, driven by a culture of learning that inspires employees to reach higher and take initiative .
that increase for tysabri also comes with an asterisk. more than 60% of the first - quarter sales increase for the drug stemmed from biogen receiving payment from the italian national medicines agency for tysabri sales in prior periods .
ibd' s take: bioverativ isn' t your typical biotech startup. it' s profitable and aiming for $ 1 billion in sales this year. head to the new america for a deeper dive into the biogen spinoff .
the third late - stage candidate in biogen' s pipeline is gazyva, which is already on the market for treating chronic lymphocytic leukemia. a phase 3 study is underway for the drug in targeting non - hodgkin' s lymphoma (nhl). as with ocrevus, though, roche owns the marketing rights for gazyva. approval for the drug in the nhl indication would be good news for biogen but not enough to offset problems for its ms franchise .
biogen executives told analysts on a call that the company hoped its ongoing direct - to - consumer tecfidera television campaign will reaccelerate u. s. growth, but it will be difficult to gauge the impact until later this year .
indeed, one reason the stocks dropped yesterday, analysts said, was that some investors had been hoping biogen would be acquired for a premium by a big pharmaceutical company and that genentech would acquire idec to gain full control of rituxan .
biogen idec said yesterday it will acquire convergence pharmaceuticals for up to $ 675 million. the buyer said its purchase was intended to speed up development of convergence’s pain drug portfolio—especially cnv1014802, a phase ii candidate that has shown promising results .
throughout the year, we welcome students at all levels and from all backgrounds to bring their passion, persistence, creativity, collaboration and focus to biogen to work alongside employees as colleagues, tackling meaningful projects and shaping their career aspirations .
biogen is truly proud to have an incredible group of teams and individuals, who not only embody our brand philosophy, “ # beyourbest” – but also advocate a healthy lifestyle, and who have achieved great things in their respective fields .
yet those systems had to be up and running before the expected food and drug administration approval of avonex came through, so biogen turned to the computer sciences corporation, a consulting and systems integration company based in newton lower falls, mass .
they put on a biogen shirt, suited up and played ,
mr. tobin said .
we started out without a contract, but at each level of detail of the project, they were right there .
but biogen' s management did count on it, sufficiently so that trials of avonex in hepatitis were suspended. this decision was as much strategic as medical, mr. tobin said. although avonex appeared to be a better drug for hepatitis than alpha interferon, it was only modestly so. moreover, hep - atitis is a huge market, primarily asia - based, where biogen would have to compete directly with its own far - larger marketing partner, schering plough .
one measure of the market' s response took biogen by surprise. after avonex was introduced in the united states, large numbers of multiple sclerosis patients called the company directly, seeking advice. in most diseases, drug companies rarely have contact with patients. but biogen executives say m. s. primarily strikes relatively young, affluent and educated white women, and the loss of control associated with the disease seemed to prompt many patients to seek greater understanding of the drug .
in october 2003, biogen idec licensed certain exclusive worldwide rights to develop and market bg - 12, oral fumarate derivative with an immunomodulatory mechanism of action, from fumapharm. biogen idec and fumapharm are evaluating bg - 12 in a range of diseases, including ms and psoriasis. in april 2005, the companies announced that the primary endpoint was met in a phase iii study designed to evaluate the efficacy and safety of bg - 12 in the treatment of moderate to severe psoriasis .
painful but necessary, the shrinkage reduced biogen' s burn rate, that quaint term high - tech startups use for cash consumption. but with product revenues still a distant promise, biogen needed a revenue source more secure than its repeated sales of equity. so mr. vincent spent the latter half of 1986 and all of 1987 renegotiating the licensing deal the company had previously signed with schering plough, for the interferons, on more favorable terms. he also signed new deals with merck, smith kline beecham and abbott for the use of patented biogen discoveries in making hepatitis vaccines and diagnostic kits. the royalty stream, just $ 1. 7 million a year in 1986, grew to $ 150 million by 1996 .
the deal was particularly rapid considering bioverativ is a rookie on wall street. biogen spun off its hemophilia business into bioverativ in february. bioverativ will pay true north $ 400 million upfront with a potential for $ 425 million in milestone payments .
current and historical pe ratio for biogen (biib) from 2006 to 2018. the price to earnings or pe ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (eps) number. the pe ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. the current pe ratio for biogen (biib) as of march 31, 2018 is 15. 78 .
the plan is to do away with about 830 jobs by the end of 2015, biogen said, an effort designed to save roughly $ 250 million in 2016 and beyond. biogen is now
in the process of notifying employees
who are losing their jobs, the company said. the decision
was extremely difficult ,
ceo george scangos said in a statement ,
but we believe these actions are necessary to fulfill our mission of bringing important new medicines to patients .
tnt009 could move bioverativ from
defensive posturing
over its hemophilia unit — spun off from biogen (biib) — to a narrative of
offensive opportunity ,
schmidt said. he expects investors to focus on the sizing opportunity for tnt009 .
analysts had been concerned biogen would provide a forecast below expectations after cautious comments by management at the recent jp morgan healthcare conference. that followed a 2015 in which the company slashed tecfidera’s growth forecast midyear and later announced a cost - saving restructuring .
biogen ($ biib) is laying off 11% of its workforce and pulling the plug on a handful of pipeline projects, cutting deep into its infrastructure amid mounting pressure and turning its attention to some high - risk r & d programs .
biogen idec and abbvie announced monday morning that their once - monthly multiple sclerosis drug daclizumab has cleared key hurdles in a phase iii study, setting the stage for a marketing pitch to regulatory authorities. for biogen idec ($ biib), the phase iii success offers a chance to expand on its blockbuster ms franchise with an imperfect but potentially lucrative new drug with some troubling side effects. and abbvie ($ abbv) has already counted this therapy as one of its top late - stage prospects .
the name bioverativ “creates a clear connection to our biogen heritage and biotech focus, ” cox said in a statement tuesday. the new company, which will be based somewhere in the boston area, will trade on the nasdaq under the symbol bivv .
the value of the fumapharm deal has not been disclosed, but its comes after biogen idec pledged $ 250 million to buy cancer specialist conforma therapeutics earlier this month, and spent $ 660 million licensing several antibody drugs from protein design labs last august .
that stumble, plus the multiple side effects of betaseron, created an opening, and biogen seized the opportunity. biogen' s scientists convinced mr. vincent and mr. tobin that avonex, which more closely mimicked the natural beta interferon protein than betaseron did, would both be more effective against multiple sclerosis and have fewer side effects than the chiron - berlex product. they designed a third clinical trial, intended to show that the drug actually slowed the progression of the disease rather than just reducing flareups .
please be on the lookout for fraudulent interview requests and job postings at the hands of an individual or entity who claims to be an employee of biogen. this fraudulent scheme relates to the unauthorized use of our company name. we consider this matter a crime and are working with law enforcement to combat this issue. please be advised that all legitimate correspondence from a biogen employee will come from
@ urltoken
email accounts. automated system response emails come from “ @ brassring. com” email addresses. there are no variations of these email addresses. biogen posts job openings on its website at urltoken if you are interested in any opportunities at biogen, please apply to current openings through our website. you will never be asked to download google hangouts or asked to submit banking information through unsecure means. if you believe that you may have been a victim of this fraud, we suggest you contact local law enforcement and actively monitor all financial accounts; those steps may help mitigate any negative impact to your personal data .
shares of both companies fell about 5 percent on a day when the market was down over all. shares of biogen fell $ 2. 25, to $ 41. 55, while idec dropped $ 2. 01, to $ 36. 96 .
in addition to gaining revenue from the development and sales of its products (both directly and through partnerships), biogen receives royalties on some patents it has licensed to other companies. for instance, the medicines company pays royalties on sales of anticoagulant angiomax .
in early 2017 biogen spun off its growing hemophilia operations into a separate, publicly traded company named bioverativ. that business' marketed products include eloctate and alprolix; the new firm continues its activities around the discovery and development of hemophilia therapies utilizing xten technology .
biogen idec, the largest massachusetts - based biotechnology company, took the compound into clinical trials to test its effectiveness against ms at different dosage levels compared to placebos. the results from late - stage trials in 2011 turned out to be better than expected .
biogen and idec pharmaceuticals announced a merger yesterday that seemed to be taken from the big pharma playbook - - an effort to cut costs and broaden product pipelines, in part because each company could not develop products fast enough on its own to sustain rapid growth .
the experimental drug has shown clinical activity in proof of concept studies for trigeminal neuralgia (tgn), and for treating pain associated with lumbosacral radiculopathy (sciatica). the experimental drug has potential applicability in several other neuropathic pain states, according to biogen idec .
biogen, inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. it offers tecfidera, avonex, plegridy, tysabri, zinbryta, and fampyra for the treatment of multiple sclerosis; ...
biogen idec’s quest for an ms pill dates back to 2006, when it bought privately held swiss drug maker fumapharm. in the process, the cambridge company acquired an experimental compound called bg - 12 being studied as an oral treatment for both ms and psoriasis.
biogen , inc. ( previously known as biogen idec ) is an american multinational biotechnology company based in cambridge , massachusetts , specializing in the discovery , development , and delivery of therapies for the treatment of neurodegenerative , hematologic , and autoimmune diseases to patients worldwide . 
biogen, inc. (previously known as biogen idec) is an american multinational biotechnology company based in cambridge, massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.
biogen, inc. (previously known as biogen idec) is an american multinational biotechnology company based in cambridge, massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases to patients worldwide.